ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA

H3 K27M-mutant gliomas often manifest as midline gliomas, have a dismal prognosis, and have no established or effective treatments at recurrence. ONC201 is the first clinical bitopic DRD2 antagonist/ClpP agonist and is under evaluation in Phase II trials for gliomas and other cancers. We previously...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Arrillaga-Romany, Isabel, Kurz, Sylvia, Sumrall, Ashley, Butowski, Nicholas, Harrison, Rebecca, DeGroot, John, Chi, Andrew, Sulman, Erik, Shonka, Nicole, Umemura, Yoshie, Odia, Yazmin, Mehta, Minesh, Iwamoto, Fabio, Leia Nghiemphu, P, Cloughesy, Timothy, Tarapore, Rohinton, Merdinger, Krystal, Oster, Wolfgang, Allen, Joshua, Batchelor, Tracy, Lassman, Andrew, Wen, Patrick
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2019
נושאים:
Adult Clinical Trials - Non-Immunologic
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847973/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.077
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים